Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus

Division of Infectious Diseases, Department of Medicine, Inflammatory Diseases Institute, and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Gastroenterology (Impact Factor: 16.72). 11/2010; 140(2):667-75. DOI: 10.1053/j.gastro.2010.10.056
Source: PubMed


Several small molecule inhibitors of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease have advanced successfully to clinical trials. However, the selection of drug-resistant mutants is a significant issue with protease inhibitors (PIs). A variety of amino acid substitutions in the protease domain of NS3 can lead to PI resistance. Many of these significantly impair the replication fitness of HCV RNA replicons. However, it is not known whether these mutations also adversely affect infectious virus assembly and release, processes in which NS3 also participates.
We studied the impact of 25 previously identified PI-resistance mutations on the capacity of genotype 1a H77S RNA to replicate in cell culture and produce infectious virus.
Most PI-resistance mutations resulted in moderate loss of replication competence, although several (V36A/L/M, R109K, and D168E) showed fitness comparable to wild type, whereas others (S138T and A156V) were severely impaired both in RNA replication and infectious virus production. Although reductions in RNA replication capacity correlated with decreased yields of infectious virus for most mutations, a subset of mutants (Q41R, F43S, R155T, A156S, and I170A/T) showed greater impairment in their ability to produce virus than predicted from reductions in RNA replication capacity. Detailed examination of the I170A mutant showed no defect in release of virus from cells and no significant difference in specific infectivity of extracellular virus particles.
Replicon-based assays might underestimate the loss of fitness caused by PI-resistance mutations, because some mutations in the NS3 protease domain specifically impair late steps in the viral life cycle that involve intracellular assembly of infectious virus.

Download full-text


Available from: David Mcgivern, Aug 13, 2014
  • Source
    • "Together with the (sub)genomic replicon, this HCVcc system has been the working horse for screening and identification of new antiviral drugs [17]. Since only recently alternative full-length isolates have been described that efficiently propagate in cell culture [18] [19] [20] [21] [22], this system has long been restricted to one specific viral isolate, designated JFH1, and intra-or inter-genotypic chimeric derivatives thereof [23]. In addition, hepatoma cells that support robust replication of HCVcc have characteristics that differ significantly from those of primary human hepatocytes, e.g., continuous proliferation, impaired innate immunity and reduced metabolic activity [24] [25]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The development and evaluation of effective therapies and vaccines for the hepatitis C virus (HCV) and the study of its interactions with the mammalian host have been hindered for a long time by the absence of suitable small animal models. Due to the narrow host tropism of HCV, the development of mice that can be robustly engrafted with human hepatocytes was a major breakthrough since they recapitulate the complete HCV life cycle. This model has been useful to investigate many aspects of the HCV life cycle, including antiviral interventions. However, studies of cellular immunity, immunopathogenesis and resulting liver diseases have been hampered by the lack of a small animal model with a functional immune system. In this review, we summarize the evolution of in vivo models for the study of HCV.
    Full-text · Article · Nov 2014 · Journal of Hepatology
  • Source
    • "Some variations appeared under the selective pressure of drugs or other factors whereas the others such as R155K are preexistent before the treatment (Colson et al., 2008; Rong et al., 2010). NS3/4A mutations were reported to impair the fitness of HCV replicons (Shimakami et al., 2011). But the drug resistant mechanisms for many mutations have not been fully understood, so there is a crucial need to explore the drug resistant mechanism, which may help to develop drug candidates effective not only to the wild-type (WT) NS3/4A protease but also to its variants. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) infection is a serious public health problem throughout the world. Great success has been achieved in developing inhibitors targeting the HCV NS3/4A protease over the past decade, but the rapid emergence of drug resistant mutations greatly compromises the efficacy of antiviral drugs or drug candidates. According to the substrate envelope hypothesis (PNAS, 2010, 107, 20986), severe drug resistant mutations would always occur where the inhibitors protrude from the substrate envelope, defined as a consensus volume occupied by the viral substrates in the active site of the NS3/4A protease. However, the substrate envelope hypothesis just qualitatively assesses the impact of mutations to a specific inhibitor, but no quantitative data is obtained. To remedy the weakness, the dynamic binding patterns of HCV NS3/4A protease inhibitors or substrates were investigated by molecular dynamics (MD) simulations and continuum solvation binding affinity predictions in this study. By comparing the quantitative binding profiles between the substrates and inhibitors, derived from the free energy decomposition analysis, we observed most residues involved in drug resistance form stronger interactions with the inhibitors than with the substrates, which is roughly coincident with the substrate envelope hypothesis and supports the general mechanism of drug resistance: the critical resistant mutations impair more to the binding of inhibitors than that of substrates. Furthermore, our predictions illustrate that the natural substrates of NS3/4A form balanced interactions with the strands 135-139 and 154-160 whereas the inhibitors cannot. Therefore, to overcome drug resistance, it may be necessary to restore the interaction balance between the two strands and the drug candidates. To our disappointment, the underlying resistant mechanisms of some mutations could not be well captured by just comparing the binding profiles of the inhibitors and substrates., and more studies should be proceeded to propose a general drug resistance mechanism.
    Full-text · Article · May 2014 · Antiviral Research
  • Source
    • "Several studies have tested the effects of vitamin A on HCV replication; these studies used a sub-genomic or full-genomic replicon, which contains 2 cistrons, one driven by HCV internal ribosome entry sites (IRES) and the other by encephalomyocarditis virus IRES78. We reported the usefulness of HCV genomes containing Gaussia princeps luciferase (GLuc) between p7 and NS2, followed by foot-and-mouth disease virus 2A, to monitor HCV RNA replication910, and this system is closer to physiological HCV replication than the bicistronic replicon systems (Fig. 1A). In addition to GLuc-containing HCV genomes in the backbone of genotype 1a H77S.3, a chimeric clone of H77S and genotype 2a JFH1, HJ3-511, with structural proteins from H77S and non-structural proteins from JFH1, we also constructed GLuc-containing genomes in the backbone of genotype 1b N12 and 2a JFH113 and confirmed their efficient replication in Huh-7.5 cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical studies suggest that the oral acyclic retinoid Peretinoin may reduce the recurrence of hepatocellular carcinoma (HCC) following surgical ablation of primary tumours. Since hepatitis C virus (HCV) infection is a major cause of HCC, we assessed whether Peretinoin and other retinoids have any effect on HCV infection. For this purpose, we measured the effects of several retinoids on the replication of genotype 1a, 1b, and 2a HCV in vitro. Peretinoin inhibited RNA replication for all genotypes and showed the strongest antiviral effect among the retinoids tested. Furthermore, it reduced infectious virus release by 80-90% without affecting virus assembly. These effects could be due to reduced signalling from lipid droplets, triglyceride abundance, and the expression of mature sterol regulatory element-binding protein 1c and fatty acid synthase. These negative effects of Peretinoin on HCV infection may be beneficial in addition to its potential for HCC chemoprevention in HCV-infected patients.
    Full-text · Article · Apr 2014 · Scientific Reports
Show more